Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma

Inclusion Criteria:

* Diagnosis of grade 1-3 follicular lymphoma with persistent, relapsed, or refractory disease to at least one prior regimen.
* No prior bortezomib therapy.
* Voluntary written informed consent.
* Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control.
* Male subject agrees to use an acceptable method for contraception for the duration of the study therapy.
* 18 years of age or older.
* aspartate aminotransferase (AST),alanine aminotransferase (ALT), total bilirubin \< 3 times the upper limit of normal unless documented by the treating physician to be secondary to underlying lymphoma.
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

Exclusion Criteria:

* Platelet count of \< 50,000 within 14 days before enrollment unless documented by the treating physician to be due to the disease.
* Absolute neutrophil count of \< 1000 within 14 days before enrollment unless documented by the treating physician to be due to disease.
* Estimated or measured creatinine clearance of less than 30 ml/min within 14 days before enrollment.
* ≥Grade 2 peripheral neuropathy within 14 days before enrollment.
* Myocardial infarction within 6 months prior to enrollment or has New York Hospital Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia.
* Patient has hypersensitivity to boron, mannitol or any drug included in the current protocol.
* Female subject is pregnant or lactating.
* Received other investigational drugs for this disease within 14 days of enrollment
* Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
* Known HIV+ status.
* Cardiac ejection fraction less than 35% at study entry measured by echocardiogram, Multigated Acquisition (MUGA) or cardiac MRI.